Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region

Reyes, Carlen; Formiga, Francesç; Coderch, Marta; Hoyo, Jordi; Férriz, Gemma; Casanovas, Josep; Monteserín, Rosa; Brotons, Carlos; Rojas, Marta; Moral, Irene

doi:10.1016/j.bone.2012.09.028

Cited by 30 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44 Psychotropic drugs, which have been previously shown to be associated with an increased risk of hip fractures [35][36][37] were more commonly used by persons with hip fracture than their controls. Consistent to previous studies, 41,45 persons with hip fracture were more likely to have epilepsy or previous fracture or stroke, which are also risk factors for falling. 11 Opioids were used more commonly among hip fracture cases compared to controls, which indicates that pain was more prevalent among cases and may be one reason for falling and fracture.…”

Section: Discussionsupporting

confidence: 88%

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Torvinen-Kiiskinen

Tolppanen

Koponen

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory. Aim To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease. Methods In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression. Results Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37). Conclusions The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.

show abstract

Section: Discussionsupporting

confidence: 88%

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Torvinen-Kiiskinen

Tolppanen

Koponen

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Postoje periferni benzodiazepinski receptori koji su dominantno lokalizovani u spoljašnjoj membrani mitohondrija. Istraživanja dokazuju da ovi receptori mogu dovoditi do modulacije u bronhomotornom tonusu [9][10][11]. Drugi, indirektan efekat benzodiazepina je takav da povećavaju neurotransmisionu aktivnost GA-BA-e na nivou postsinaptičkih receptora kao i na nivou svih neuroaksona u centralnom nervnom sistemu [8].…”

Section: Uvodunclassified

“…Benzodiazepini su lijekovi koji imaju direktne i indirektne bronhodilatatorne efekte na glatku muskulaturu disajnih puteva [9,10]. Direktan efekat ispoljavaju inhibišući voltažno zavisne Ca²+ kanale, a indirektan pojačavajući neurotransmisionu ulogu GABA na nivou postsinaptičkih receptora, a rezultat toga je porast broja otvorenih kanala za hlor [4,7].…”

Section: Diskusijaunclassified

“…Smatra se da su ove ćelije odgovorne za respiratornu depresiju poslije davanja muscimola. Dokazano je da benzodiazepini davani lokalno na površne strukture intermedijarne zone mogu da prouzrokuju pad tonusa glatke muskulature disajnih puteva, prije nego djelovanjem na dublje neurone dorzalne grupe vagusa i nukleusa ambigusa koji inervišu eferentnim nervnim putem disajno stablo [4,10,13].…”

Section: Diskusijaunclassified

“…Sa druge strane, GABA-B receptorski agonist, baklofen, može pojačati odgovor disajnih puteva imitirajući dejstvo histamina kod astmatičnih pacijenata. Ovo paradoksalno dejstvo baklofena vodi nas ka hipotezi da možda postoje postganglionski GABA-B receptori koji vežu Gi protein, za koji se zna da slabi relaksaciju glatke muskulature disajnih puteva [9,10,11].…”

Section: Diskusijaunclassified

See 2 more Smart Citations

Efekat benzodiazepina na kontrakciju preparisane traheje zamorca izazvane histaminom

Mirić¹,

Joksimović²,

Mijović³

et al. 2012

Biomedicinska istraž.

View full text Add to dashboard Cite

Kratak sadržajUvod. Disajni putevi su biološke strukture koje se šire i skupljaju mijenjajući volumen pluća i tonus bronha. Gama-amino buterična kiselina (GABA) je neurotransmiter koji je značajan inhibitor u centralnom nervnom sistemu sisara. Benzodiazepini su lijekovi koji imaju direktan bronhodilatatorni efekat na glatku muskulaturu disajnih puteva. Oni učestvuju u količini otpuštenog acetilholina i odgovora mišića na nadražaj. Cilj istraživanja je bio da se utvrdi da li benzodiazepini redukuju kontrakciju izolovane traheje zamorca koja je indukovana histaminom.Metode. Mjerena je tenzija glatke muskulature traheje zamorca čija je kontrakcija indukovana histaminom. Korišćeno je 10 zamoraca oba pola, prosječne težine od 610 g. Pripremljeni preparat traheje zamorca tretiran je rastućim koncentracijama histamina od 0,01, 0,1 i 1,0 mg/mL pri čemu je konstriktorni odgovor registrovan fiziografom firme Godart "Fersttransducer" na višekanal-nom pisaču "Watanable". Preparat je ispiran Krebsovim rastvorom, a poslije ponovne stabilizacije postupak se ponavljao uz dodavanje benzodiazepina u rastućim koncentracijama.Rezultati. Prethodna inkubacija trahealnih prstenova zamorca benzodiazepinom u koncentraciji od 0,014 mg/mL smanjila je kontraktilnu sposobnost traheje indukovanu sa 0,01 mg/mL histamina za 82,3%. Korišćenje benzodiazepina u koncentraciji od 0,028 mg/mL smanjilo je kontrakciju za 85,2%, a koncentracija benzodiazepina od 0,042 mg/mL dovela je do najvećeg pada kontraktilnosti za 88,2%.Zaključak. Dobijeni rezultati ukazuju da veće koncentracije benzodiazepina smanjuju kontraktilnu sposobnost traheje izazvane histaminom.

show abstract

Proton-pump inhibitors and risk of fractures: an update meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region

Cited by 30 publications

References 23 publications

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Efekat benzodiazepina na kontrakciju preparisane traheje zamorca izazvane histaminom

Proton-pump inhibitors and risk of fractures: an update meta-analysis

Contact Info

Product

Resources

About